Kornitzer Capital Management Inc. KS Has $5.49 Million Holdings in Roche Holding AG (OTCMKTS:RHHBY)

Kornitzer Capital Management Inc. KS increased its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 1.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 136,923 shares of the company’s stock after purchasing an additional 1,798 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Roche were worth $5,490,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. AlphaMark Advisors LLC acquired a new stake in shares of Roche during the third quarter worth $149,000. Diversified Trust Co grew its stake in Roche by 6.4% in the third quarter. Diversified Trust Co now owns 59,742 shares of the company’s stock valued at $2,396,000 after acquiring an additional 3,613 shares during the period. GAMMA Investing LLC grew its stake in Roche by 57.7% in the third quarter. GAMMA Investing LLC now owns 7,944 shares of the company’s stock valued at $317,000 after acquiring an additional 2,906 shares during the period. Bard Financial Services Inc. grew its stake in Roche by 112.1% in the third quarter. Bard Financial Services Inc. now owns 66,500 shares of the company’s stock valued at $2,657,000 after acquiring an additional 35,150 shares during the period. Finally, Norman Fields Gottscho Capital Management LLC grew its stake in Roche by 5.5% in the third quarter. Norman Fields Gottscho Capital Management LLC now owns 26,000 shares of the company’s stock valued at $1,039,000 after acquiring an additional 1,350 shares during the period.

Roche Trading Up 1.1 %

RHHBY opened at $38.17 on Friday. The business’s 50-day simple moving average is $39.55 and its 200 day simple moving average is $36.79. Roche Holding AG has a 52-week low of $29.20 and a 52-week high of $42.43.

Analyst Ratings Changes

RHHBY has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft cut Roche from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Bank of America raised Roche from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Roche presently has a consensus rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.